Lifetree Clinical Research Expands Research Bed Capacity
Lifetree Clinical Research
has expanded its in-patient capacity from 60 to 75 beds in the early stage research unit at the 35,000-square-foot facility located at 700 E. 3838 S. in Salt Lake City, Utah. This expansion represents a greater than 100 percent increase in size since Lifetree Clinical Research was founded in 2003 at the same address as a 5,000-square-foot facility with eight beds.
The 25 percent increase in beds will allow Lifetree to conduct larger Phase I clinical research studies and support expansion into early stage research in new therapeutic areas such as experimental human models, Alzheimer’s disease, Hepatitis C, and broadened Neuropsychiatric capabilities. Despite an uncertain climate facing many of the nation’s contract research organizations, many of which reduced or eliminated bed capacity over the last four years, Lifetree continues to experience record growth and an expanding client base representing many of the nation’s leading pharmaceutical and biotech research and development companies.
Lifetree currently employs more than 100 Salt Lake City area residents in addition to other supporting personnel throughout the United States.
Unlock Commercial Growth through Data-Driven Patient and HCP Insights
May 2nd 2025Leveraging data-driven patient and healthcare provider (HCP) insights, including social drivers of health (SDOH), is essential for life sciences companies to continuously improve patient engagement and commercial success. Mark Rodgers, AVP of Commercial Analytics at Inovalon, discusses how identifying treatment milestones, assessing HCP performance, and segmenting patient populations using SDOH data can drive targeted strategies that improve healthcare outcomes and market access
Improving Relationships and Diversifying the Site Selection Process
April 17th 2025In this episode of the Applied Clinical Trials Podcast, Liz Beatty, co-founder and chief strategy officer, Inato, discusses a number of topics around site engagement including community-based sites, the role of technology in improving site/sponsor relationships, how increased operational costs are impacting the industry, and more.
FDA Approves Nipocalimab for the Treatment of Generalized Myasthenia Gravis
April 30th 2025Approval is based on results from the pivotal Vivacity-MG3 trial in which IMAAVY (nipocalimab-aahu) demonstrated superior disease control throughout 24 weeks when compared to placebo plus standard of care.
